Akebia Therapeutics AKBA Stock
Akebia Therapeutics Price Chart
Akebia Therapeutics AKBA Financial and Trading Overview
| Akebia Therapeutics stock price | 1.32 USD |
| Previous Close | 1.18 USD |
| Open | 1.18 USD |
| Bid | 1.14 USD x 3200 |
| Ask | 1.17 USD x 3100 |
| Day's Range | 1.13 - 1.23 USD |
| 52 Week Range | 0.24 - 1.63 USD |
| Volume | 1.87M USD |
| Avg. Volume | 1.63M USD |
| Market Cap | 211.96M USD |
| Beta (5Y Monthly) | 0.724295 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.28 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3 USD |
AKBA Valuation Measures
| Enterprise Value | 254.61M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.125 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.7820459 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 0.939 |
| Enterprise Value/EBITDA | 7.623 |
Trading Information
Akebia Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.724295 |
| 52-Week Change | 233.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.63 USD |
| 52 Week Low | 0.24 USD |
| 50-Day Moving Average | 0.97 USD |
| 200-Day Moving Average | 0.63 USD |
AKBA Share Statistics
| Avg. Volume (3 month) | 1.63M USD |
| Avg. Daily Volume (10-Days) | 1.77M USD |
| Shares Outstanding | 185.93M |
| Float | 168M |
| Short Ratio | 2.35 |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 29.14% |
| Shares Short | 5.15M |
| Short % of Float | 2.79% |
| Short % of Shares Outstanding | 2.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -20.79% |
| Operating Margin (ttm) | -1.57% |
| Gross Margin | 55.84% |
| EBITDA Margin | 12.32% |
Management Effectiveness
| Return on Assets (ttm) | -0.65% |
| Return on Equity (ttm) | -958.14% |
Income Statement
| Revenue (ttm) | 271.03M USD |
| Revenue Per Share (ttm) | 1.47 USD |
| Quarterly Revenue Growth (yoy) | -35.00000000000000000000000000000000% |
| Gross Profit (ttm) | 141.8M USD |
| EBITDA | 33.4M USD |
| Net Income Avi to Common (ttm) | -56358000 USD |
| Diluted EPS (ttm) | -0.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 56.95M USD |
| Total Cash Per Share (mrq) | 0.31 USD |
| Total Debt (mrq) | 82.87M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.455 |
| Book Value Per Share (mrq) | -0.077 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -69072000 USD |
| Levered Free Cash Flow (ttm) | 10.03M USD |
Profile of Akebia Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 245 First Street |
| ZIP | 02142 |
| Phone | 617 871 2098 |
| Website | https://www.akebia.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 204 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Q&A For Akebia Therapeutics Stock
What is a current AKBA stock price?
Akebia Therapeutics AKBA stock price today per share is 1.32 USD.
How to purchase Akebia Therapeutics stock?
You can buy AKBA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akebia Therapeutics?
The stock symbol or ticker of Akebia Therapeutics is AKBA.
Which industry does the Akebia Therapeutics company belong to?
The Akebia Therapeutics industry is Biotechnology.
How many shares does Akebia Therapeutics have in circulation?
The max supply of Akebia Therapeutics shares is 231.58M.
What is Akebia Therapeutics Price to Earnings Ratio (PE Ratio)?
Akebia Therapeutics PE Ratio is now.
What was Akebia Therapeutics earnings per share over the trailing 12 months (TTM)?
Akebia Therapeutics EPS is -0.28 USD over the trailing 12 months.
Which sector does the Akebia Therapeutics company belong to?
The Akebia Therapeutics sector is Healthcare.
Akebia Therapeutics AKBA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}